Year None202420232022202120202019201820172016 Date Latest Press Release February 6, 2019 Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan February 4, 2019 Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans January 7, 2019 Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors December 19, 2018 Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies December 18, 2018 Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection December 17, 2018 Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection December 11, 2018 Eiger BioPharmaceuticals Reports on 2018 R&D Day December 4, 2018 Eiger BioPharmaceuticals to Host R&D Day in New York City December 3, 2018 Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer December 3, 2018 Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies Pagination First page « first Previous page ‹ previous … Page 10 Page 11 Page 12 Page 13 Current page 14 Page 15 Page 16 Page 17 Page 18 … Next page next › Last page last »